Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...